Tech Company Financing Transactions

CytoReason Funding Round

CytoReason, based in Tel Aviv-Yafo, secured $80 million in investment from NVIDIA, OurCrowd and Pfizer Venture Investments.

Transaction Overview

Company Name
CytoReason
Announced On
7/17/2024
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Undisclosed
Investors

NVIDIA (Lead Investor)

OurCrowd (Lead Investor)

Pfizer Venture Investments (Lead Investor)

Thermo Fisher Scientific (Lead Investor)

Bank Hapoalim

Proceeds Purpose
The company intends to use the investment to expand the application of its models into additional indications, grow its proprietary molecular and clinical data, and establish an office in Cambridge, MA, later this year.

Company Information

Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Azrieli Circular Tower, 16th floor Derech Menachem Begin 132
Tel Aviv-Yafo, 6701101
Israel
Phone
Undisclosed
Website
www.cytoreason.com
Email Address
[email protected]
Overview
The volume of human molecular data is growing exponentially, but our analytic capabilities are growing linearly, at best. Humans alone cannot process all this data. What's needed is a technology capable of digesting, organizing and making sense of all data types and sources. We founded CytoReason in 2016 to address this problem. Our computational disease models are designed to gather impossible amounts of data from countless indications and treatments.
Profile
CytoReason LinkedIn Company Profile
Social Media
CytoReason Company Twitter Account
Company News
CytoReason News
Facebook
CytoReason on Facebook
YouTube
CytoReason on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
David Harel
  David Harel LinkedIn Profile  David Harel Twitter Account  David Harel News  David Harel on Facebook
Chief Medical Officer
Yehuda Chowers
  Yehuda Chowers LinkedIn Profile  Yehuda Chowers Twitter Account  Yehuda Chowers News  Yehuda Chowers on Facebook
Chief Operating Officer
Yael Villa
  Yael Villa LinkedIn Profile  Yael Villa Twitter Account  Yael Villa News  Yael Villa on Facebook
Chief Scientific Officer
Adir Katz
  Adir Katz LinkedIn Profile  Adir Katz Twitter Account  Adir Katz News  Adir Katz on Facebook
Chief Scientific Officer
Shai Shen-Orr
  Shai Shen-Orr LinkedIn Profile  Shai Shen-Orr Twitter Account  Shai Shen-Orr News  Shai Shen-Orr on Facebook
Co-Founder
Elina Starosvetsky
  Elina Starosvetsky LinkedIn Profile  Elina Starosvetsky Twitter Account  Elina Starosvetsky News  Elina Starosvetsky on Facebook
VP - Finance
Ofek Levy
  Ofek Levy LinkedIn Profile  Ofek Levy Twitter Account  Ofek Levy News  Ofek Levy on Facebook
VP - Human Resources
Michal Katzir
  Michal Katzir LinkedIn Profile  Michal Katzir Twitter Account  Michal Katzir News  Michal Katzir on Facebook
VP - Product Management
Oshrat Kfir
  Oshrat Kfir LinkedIn Profile  Oshrat Kfir Twitter Account  Oshrat Kfir News  Oshrat Kfir on Facebook
VP - R & D
Yoav Aharoni
  Yoav Aharoni LinkedIn Profile  Yoav Aharoni Twitter Account  Yoav Aharoni News  Yoav Aharoni on Facebook

 

 

Browse more venture capital transactions:

Prev: 7/17/2024: Xapien venture capital transaction
Next: 7/17/2024: Tribe AI venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.